Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Summary not available.
Haemonetics Corporation (NYSE: HAE) has announced the schedule for its fourth quarter and fiscal year 2023 financial results. The results will be published on May 11, 2023, at 6:00 am ET, followed by a conference call with investors and analysts at 8:00 am ET the same day. Investors can access the call via a teleconference link provided in the announcement. Additionally, a live webcast will be available on the Haemonetics investor relations website. A replay of the call will be accessible for one year after the event. Haemonetics focuses on innovative medical products aimed at improving patient care and reducing healthcare costs, particularly in blood and plasma component collection and transfusion services.
Haemonetics Corporation (NYSE: HAE) announced the release of its first Corporate Responsibility Report on April 20, 2023. The report outlines the company's progress in environmental, social, and governance (ESG) initiatives for the fiscal year 2022, concluding on April 2, 2022. Key highlights include:
- Human capital initiatives aimed at attracting a diverse workforce.
- Results from the company's first greenhouse gas emissions assessment.
- Information on corporate governance, ethics, product safety, and cybersecurity.
CEO Christopher A. Simon emphasized the importance of addressing ESG risks and maintaining stakeholder trust. The report is available on Haemonetics' website.
Vivasure Medical announced its pivotal PATCH Clinical Study for the PerQseal® Closure Device has received FDA Investigational Device Exemption (IDE) approval. The study will enroll up to 188 patients in the U.S. and Europe, aiming for FDA pre-market approval and commercial launch by year-end 2023. The company also secured a €30 million strategic investment from Haemonetics as part of its Series D financing, with an option for acquisition upon milestone completion. The global market for large hole vessel closure is valued at over $300 million, with strong growth potential, emphasizing the significance of this partnership and study.
Haemonetics Corporation (NYSE: HAE) has received 510(k) clearance from the U.S. Food and Drug Administration for its next-generation Intelligent Control software for the Cell Saver Elite+ Autotransfusion System. This upgrade includes over 50 automation enhancements aimed at improving efficiency and user experience. The Cell Saver technology allows hospitals to recover patients' blood during surgeries, helping prevent unnecessary transfusions. The software upgrade enhances versatility, offering features such as Manual Mode and optimized wash volumes according to industry standards.
Haemonetics Corporation (NYSE: HAE) has announced that President and CEO Chris Simon will engage with investors during a fireside chat at the Raymond James 44th Annual Institutional Investors Conference on March 6, 2023, at 8:40 a.m. ET. The chat will be accessible via a live webcast on Haemonetics' Investor Relations website. After the event, a replay will be available for 90 days. Haemonetics specializes in innovative medical products aimed at improving patient care and lowering healthcare costs across critical medical markets, including blood and plasma collection.
Haemonetics Corporation (NYSE: HAE) announced that its third quarter fiscal 2023 financial results are accessible on its Investor Relations website. The reporting period ended on December 31, 2022. Investors and analysts are invited to a conference call on February 7, 2023, at 8:00 a.m. ET, to discuss these results. A live webcast will also be available. Earnings release and analytical tables have been posted online for review. For further information, visit Haemonetics' website.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2023 financial results on February 7, 2023, at 6:00 AM ET. A conference call for investors and analysts will follow at 8:00 AM ET on the same day, allowing participants to discuss the results and ask questions. Registration is required to access the call, and a live webcast will also be available on the company's investor relations website. A replay of the call will be accessible for one year post the event.
Haemonetics Corporation (NYSE: HAE) announced that President and CEO Chris Simon will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2023, at 2:15 PM Pacific time. The live presentation will be available via audio webcast, accessible through Haemonetics' Investor Relations website. A replay will be available for 30 days after the event. Haemonetics focuses on innovative medical solutions aimed at improving patient care and reducing healthcare costs, specifically in blood and plasma component collection.
Haemonetics Corporation (NYSE: HAE) announced that its financial results for the second quarter of fiscal 2023, ending October 1, 2022, are now available on its Investor Relations website. A conference call and webcast will occur at 8:00 a.m. ET on November 7, 2022, to discuss these results. Interested parties can access the earnings release and supplemental information via provided links. A replay will be available for one year after the conference call. Haemonetics focuses on innovative medical products for improving patient care and reducing healthcare costs.